Unicycive Therapeutics (UNCY) News Today

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is under pressure as multiple law firms publicized a securities class action and November 2, 2026 lead-plaintiff deadline. The legal news adds to investor concerns about the company’s FDA and manufacturing disclosures, while the stock has already fallen 21.4% over the past four weeks and is trading near its 52-week low.

• Positive Sentiment: Zacks reported that UNCY appears technically oversold after its recent decline. Analysts have also been raising earnings estimates, which could support a potential short-term rebound, although this is a technical and sentiment-based argument rather than a change in the company’s fundamentals. Zacks analysis of Unicycive Therapeutics
• Neutral Sentiment: Several investor-rights firms, including Kaplan Fox, Rosen Law Firm, Faruqi & Faruqi, and Levi & Korsinsky, reminded investors that November 2, 2026 is the deadline to seek appointment as lead plaintiff in the securities lawsuit. These announcements largely repeat existing litigation information and are primarily solicitations for affected shareholders. Kaplan Fox deadline announcement
• Negative Sentiment: The class action alleges that Unicycive told shareholders to expect an FDA decision on June 29, 2026 and a commercial launch of oxylanthanum carbonate later in 2026, while allegedly failing to inspect a third-party manufacturing facility that had previously resulted in a Complete Response Letter. The allegations raise risks surrounding FDA compliance, launch timing, potential liability, and investor confidence; they have not been proven in court. Unicycive shareholder alert
• Negative Sentiment: A related notice names Unicycive’s chief executive and chief financial officers as defendants under “control person” claims, alleging they oversaw disclosures stating that the manufacturer had made significant FDA-compliance progress without the company independently verifying that progress through an inspection. Levi and Korsinsky shareholder alert